Crinetics (CRNX)’ paltusotine was granted FDA orphan designation status as a treatment of carcinoid syndrome, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position
- Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
- Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating
- Buy Rating Affirmed for Crinetics Pharmaceuticals: Promising Phase 3 Trial of Atumelnant for CAH
- Crinetics Pharmaceuticals Reports Q1 2025 Financial Results